Rally Researchers

$

Sign up for our emails!

Fill out my online form.

Recent Posts

Rally Researchers

What are Oncolytic Viruses?

What are Oncolytic Viruses?

A key part of Rally’s mission is to find better treatments with fewer long-term side effects, and for almost a decade. Rally has invested for almost a decade in oncolytic virus treatments. A promising, cutting-edge, targeted immunotherapy. Oncolytic viruses are genetically modified viruses or naturally occurring viruses that are reprogrammed to selectively replicate in cancer cells killing the cancer without damaging normal cells. Pretty cool. Josh Bernstock, M.D., Ph.D., shares, “Oncolytic...

read more
New and Innovative Study Technique for Osteosarcoma Metastasis

New and Innovative Study Technique for Osteosarcoma Metastasis

Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In metastatic osteosarcoma, the cancer spreads from the primary bone site to another location, most often the lungs. It can also spread to other bones, the brain or other organs. Currently there are no curative treatments for metastatic osteosarcoma. We urgently need to develop new therapies. To better understand a disease, it is common for tumor research studies to...

read more
INSTRuCT Database for Rhabdomyosarcoma Impact

INSTRuCT Database for Rhabdomyosarcoma Impact

Rally is proud to be the initial funder for the creation of the INSTRuCT Database with a Consortium Grant to Dr. Sam Volchenboum of the Pediatric Cancer Data Commons (PCDC) at the University of Chicago. Recent advances in genomic medicine look promising in the study of rhabdomyosarcoma (RMS). RMS is a rare soft tissue malignancy primarily diagnosed before adolescence.   RMS studies are historically challenged, given that only approximately 350 patients are diagnosed with RMS each year in the...

read more
New RNA Therapies for Glioblastoma from Small Phase 1 Study

New RNA Therapies for Glioblastoma from Small Phase 1 Study

Glioblastoma (GBM) in children and adults is a deadly brain tumor with a poor prognosis. Current treatment includes surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy. Unfortunately, most patients still experience tumor growth despite the treatment and have a median survival of less than two years.  Immunotherapy has shown success in the treatment of other types of tumors, but that success has been elusive with malignant brain tumors, such as GBM....

read more
What is Big Data and Childhood Cancer Research

What is Big Data and Childhood Cancer Research

After being born and living in Turkey my whole life, I came to the US for college to study biological sciences at the University of Chicago. When the laboratory research internship I found for the summer of my first year was cancelled due to COVID-19, I joined a resume match program of my school’s Career Advancement Office, which matched students with employers based on experience and preferences. It was initially through this program that I matched with the Pediatric Cancer Data Commons...

read more
The Spark Has Ignited A Fire: How Rally’s Seed Funding Paved the Way for Dr. Volchenboum and the PCDC

The Spark Has Ignited A Fire: How Rally’s Seed Funding Paved the Way for Dr. Volchenboum and the PCDC

At Rally Foundation for Childhood Cancer Research, we often describe ourselves as “philanthropic seed investors in the next great discovery.” That’s because Rally invests early and continues to invest as projects make progress. It’s also because we like to take a few risks when it comes to funding the more “unconventional” research projects. After all, it only takes one spark to light a fire, and that spark—that next great discovery—could pave the way to finding a cure. Dr. Sam Volchenboum’s...

read more

$

Sign up for our emails!

Fill out my online form.

Recent Posts

Volunteers are the heart of Rally's mission!

 

Enter your email below to receive details about our volunteer opportunities.

Thank you for your interest in volunteering with Rally! You should receive an email shortly with additional details.